- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
- You can view the full Merck Ratings Report.
Merck's (MRK) Keytruda treatment improved the survival rate of patients with bladder cancer who previously underwent treatment.
Look for solid companies showing life.
Here are Thursday's top research calls, including upgrades for Anadarko Petroleum, GrubHub and Merck, and a downgrade for Pfizer.